Abstract

A 42‐mg daily dose of the antipsychotic lumateperone improved depressive symptoms relative to placebo in patients with bipolar disorder, a 6‐week study has found. The Phase 3 study also reported that participants receiving lumateperone experienced few serious adverse events. Study results were published online Sept. 23, 2021, in the American Journal of Psychiatry.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call